FDA Grants Priority Review for New Leukemia Option

The FDA has granted priority review status for two new indications of dasatinib (Sprycel), according to the drug ’s developer.

Source: CancerNetwork - July 20, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia Hematologic Malignancies & Lymphoma News Pediatric Cancers Source Type: news